期刊名称：CLINICAL LIPIDOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The field of lipidology research is on the cusp of major advances that will impact the health community in numerous ways. Recent studies demonstrating that an elevated LDL-C level significantly contributes to the development of coronary heart disease indicate that the impact of lipid-related illnesses is set to impose a huge burden on healthcare in the coming years, thus the development of novel LDL-C lowering therapies is essential.
The emerging field of HDL-based therapeutics is proving to be an important area of study, with a number of compounds currently in clinical trials. Research into the molecular biology of lipid disorders, such as dyslipidemia, lipid transport disorders and the role of genetic inheritance (e.g., in the case of familial hypercholesterolemia) is more important today than ever before. An expanding area of research is the use of liposomes for the targeted delivery of drugs or therapeutic genes for the treatment of diseases such as cancer.
In the light of development of an extensive range of statin therapies, Clinical Lipidology aims to provide a forum for new clinical findings, therapeutic overviews of optimal treatment strategies and commentary on future trends, including combination strategies, as well as cutting edge translational research, and will provide the increasingly time-constrained scientific community with an accessible and definitive resource covering all aspects of lipids in health and disease. Key advances in the field are reported and analyzed by international experts, providing an authoritative, but accessible, forum for this increasingly important area of research.
Coverage includes:
- Obesity and the metabolic syndrome
- Related cardiovascular diseases, such as atherosclerosis
- Treatment of lipid-related disorders
- Reviews of more established drugs and their use in new dosing regimens and combinations
- Cost-effectiveness of therapeutics
- Side effects of lipid-lowering medication
- Preventive medicine
- Dietary prevention
- Summaries of newly approved therapeutic agents
- Results of recent clinical trials relevant to the field of lipidology
- Diagnostic and clinical criteria
- Research in emerging areas such as the use of liposomes for drug delivery and gene therapy
Clinical Lipidology delivers this essential information in concise, at-a-glance article formats to provide an accessible forum for the lipidology community.
Instructions to Authors
Editorial policy
Future Medicine titles endorse the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors, and Code of Conduct for Editors of Biomedical Journals, produced by the Committee on Publication Ethics. Our full Editorial Policy can be found in the Author Guidelines.
Manuscript submission & processing
Future Medicine titles publish solicited and unsolicited articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to external review. Initial screening of articles by internal editorial staff will assess the topicality and importance of the subject, the clarity of presentation, and relevance to the audience of the journal in question.
If you are interested in submitting an article, or have any queries regarding article submission, please contact the Managing Commissioning Editor for the journal (see Contact Us). For new article proposals, the Managing Commissioning Editor will require a brief article outline and working title in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under guidance from the Editorial Advisory Panel, solicits articles directly for publication.
External peer review
Through a rigorous peer review process, our titles aim to ensure that articles are unbiased, scientifically accurate and clinically relevant. All articles are peer reviewed by three or more members of the International Advisory Board or other specialists selected on the basis of experience and expertise. Review is performed on a double-blind basis 鈥?the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal (see Conflict of Interest Policy below). Peer reviewers complete a referee report form, to provide general comments to the editor and both general and specific comments to the author(s).
Where an author believes that an editor has made an error in declining a paper, they may submit an appeal. The appeal letter should clearly state the reasons why the author(s) considers the decision to be incorrect and provide detailed, specific responses to any comments relating to the rejection of the article. Further advice from members of the journal鈥檚 Editorial Advisory Panel external experts will be sought regarding eligibility for re-review.
Revision
Most manuscripts require some degree of revision prior to acceptance. Authors should provide two copies of the revised manuscript 鈥?one of which should be highlighted to show where changes have been made. Detailed responses to reviewers鈥?comments, in a covering letter/email, are also required. Manuscripts may be accepted at this point or may be subject to further peer review. The final decision on acceptability for publication lies with the journal editor.
Post-acceptance
Accepted manuscripts are edited by the in-house editorial team. Authors will receive proofs of their article for approval and sign-off and will be asked to sign a transfer of copyright agreement, except in circumstances where the author is ineligible to do so (e.g. government employees in certain countries).
Self-archive policy
Our self-archiving policies are set out below. These differ according to the copyright status of the article. Authors should adopt the self-archiving policy corresponding to the publishing route that they have opted for. The first section sets out the policy applicable for instances where copyright is assigned to the publisher. The subsequent section explains the rights applicable where an author has chosen the open access option.
Where copyright is assigned to the publisher
This rights outlined here apply in circumstances where copyright has been assigned to the publisher.
i) Manuscripts that have been submitted for publication and entry into peer review
Once a manuscript has been submitted for publication and entered into peer review, authors may share print or electronic copies of an article with colleagues. In doing so, they should state that the article has been submitted for publication to [the specified journal]. The author(s) may also post an electronic version of an article on a personal website, the website of an employer or institution, or to free public servers.
ii) Post-acceptance
Once a manuscript has been accepted for publication, authors may share print or electronic copies of their version of an article with colleagues (not the final published version), use all or part of an article in other publications and use the article for educational or research purposes. Three months after publication, and subject to appropriate acknowledgment of the journal and full bibliographic reference for an article, authors may post their version of the article on a personal website. Twelve months after publication, and subject to appropriate acknowledgment of the journal and full bibliographic reference for an article, authors may post their version of the article on a personal website, their employer鈥檚 website or on free public servers in their subject area. Requests to post their version of the article on institutional or commercial websites, etc, within 12 months of publication should be directed to the publisher.
Requests for posting of the final published version on personal, institutional or commercial websites should be directed to the publisher.
Authors cannot reproduce an article for commercial purposes (i.e. for monetary gain on their own account or on that of a third party, or for indirect financial gain by a commercial entity). However, this does not affect an author鈥檚 rights to receive a royalty or other payment for works of scholarship.
Articles published via the open access option
The rights outlined below apply specifically to all articles published via the open access option route.
Provided that authors give appropriate acknowledgment to the journal and publisher, and cite the full bibliographic reference for the article when it is published, authors may share print or electronic copies of an article with colleagues, use all or part an article and abstract in personal compilations or other scholarly publications of their own work (and may receive a royalty or other payment for such work), use an article within their employer鈥檚 institution or company for educational or research purposes, including use in course packs.
Authors publishing via open access option route may post the final PDF of the article on their own personal website, on an employer鈥檚 website and on free public servers in their subject area. Electronic versions of an accepted article should include a link to the published version of the article together with the following: 鈥楩or full bibliographic citation, please refer to the version available at www.futuremedicine.com鈥?
Third parties are entitled to use an article published via the open access option route, in whole or in part, in accordance with the conditions outlined in the Creative Commons Deed, Attribution 2.5 Non-Commercial (further details from www.creativecommons.org), which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission. Please address any queries to permissions@futuremedicine.com.
Editorial Board
All staff can be contacted at:
Future Medicine Ltd
Unitec House
2 Albert Place
London
N3 1QB
UK
E-mail: info@futuremedicine.com
Business Office:
Tel +44 (0)20 8371 6080
Fax +44 (0)20 8371 6099
Editorial Office:
Tel: +44 (0)20 8371 6090
Fax: +44 (0)20 8343 2313
Future Science Group journals will be exhibited at a wide variety of international clinical, library and information related meetings. Visit our booth in the exhibit halls to meet members of the team and to pick up free copies of the relevant journal(s). A full list of meetings can be found here.
Management
Chairman:
James Drake
Managing Director:
David Hughes
Editorial
Editorial Director:
Elisa Manzotti
Head of Production:
Karen Rowland
Head of Commissioning:
Charlotte Barker
Journal Development Manager:
Laura Dormer
For a full list of editorial contacts, please click here
Reprints, Permissions & Translations
Reprints Manager:
Sam Cavana
General Enquiries:
reprints@futuremedicine.com
Special Projects
Special Projects Manager:
Elisa Manzotti
Sales and Marketing Enquiries
Sales & Marketing Manager:
Simon Boisseau
General Enquiries:
sales@futuremedicine.com
Electronic Access Enquiries
Electronic Resources Manager:
Matthew Connolly
Subscription Enquiries
UK, USA, Europe, Rest of World
Future Medicine Ltd
Unitec House
2 Albert Place
London
N3 1QB
UK
Tel +44 (0)20 8371 6080
Fax +44 (0)20 8371 6099
E-mail (UK): sales@futuremedicine.com
E-mail (North America): sales.us@futuremedicine.com
Far East and Australasia (excluding Japan)
I Group Asia Pacific
Flat A, 31F.
Morrison Plaza
5-9A, Morrison Hill Road
Wanchai, Hong Kong
Tel: +852 2572 7228
Fax: +852 25758822
E-mail: info.hk@igroupnet.com
Japan
Technomics, Inc.
Ohku Building Kyobashi,
1-16-10 Kyobashi
Chuoku, Tokyo 104-0031
Japan
Tel: +81 (0)3 3538 2531
Fax: +81 (0)3 3538 2537
E-mail: sales@technomics.co.jp
Latin America and the Caribbean
Systems Link International
2671 W.81 Street, Hialeah, Florida, FL 33016 USA
Tel: +1 305 826 6191
Fax: +1 305 826 6195
E-mail: informacion@systemsint.info
China
Charlesworth China
12th Floor, Xian Dai Bai Li Dasha
(Beijing Modern Palace Building)
No. 20 Daluyuan Dongsanhuan Nanlu
Chaoyang District
Beijing 100022
China
Tel: +86 10 6779 1601
E-mail: sales@charlesworth.com.cn
Editorial
Commissioning
Aging Health
Future Virology
International Journal of Clinical Rheumatology
Therapy
Women鈥檚 Health
Managing Commissioning Editor: Charlotte Barker
Future Cardiology
Pediatric Health
Personalized Medicine
Pharmacogenomics
Managing Commissioning Editor: Tarryn Greenberg
Clinical Lipidology
Future Microbiology
Future Neurology
Future Oncology
HIV Therapy
Managing Commissioning Editor: Victoria Lane
Biomarkers in Medicine
Commissioning Editor: Laura Dormer
Immunotherapy
Commissioning Editor: Duc Hong Le
Nanomedicine
Commissioning Editor: Morag Robertson
Regenerative Medicine
Editor: Elisa Manzotti
Commissioning Editor: Charlotte Barker
Production
Future Oncology
International Journal of Clinical Rheumatology
Personalized Medicine
Pharmacogenomics
Therapy
Managing Production Editor: Helen McGrath
Aging Health
Clinical Lipidology
Future Cardiology
Future Neurology
Immunotherapy
Pediatric Health
Women鈥檚 Health
Managing Production Editor: Kathryn Berry
Biomarkers in Medicine
Future Microbiology
HIV Therapy
Nanomedicine
Regenerative Medicine
Future Virology
Managing Production Editor: Stacy Crouch
| 
刊名字顺( Alphabetical List of Journals):
返回页首 